Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Abiomed Inc Reaffirms FY 2013 Revenue Guidance


Wednesday, 6 Feb 2013 07:00am EST 

Abiomed Inc announced that it is maintaining its fiscal 2013 revenue guidance in a range of $155 million to $157 million, representing annual growth of 23% to 24%, with worldwide Impella revenues forecast to grow greater than 30%. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $156 million for fiscal 2013. 

Company Quote

25.77
0.49 +1.94%
22 Jul 2014